about
A Perspective of Immunotherapy for Prostate CancerEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsChimaeric antigen receptor T-cell therapy for tumour immunotherapy.Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.The cytosolic domain of T-cell receptor ζ associates with membranes in a dynamic equilibrium and deeply penetrates the bilayer.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chimeric antigen receptor-modified T cells strike back.
@en
Chimeric antigen receptor-modified T cells strike back.
@nl
type
label
Chimeric antigen receptor-modified T cells strike back.
@en
Chimeric antigen receptor-modified T cells strike back.
@nl
prefLabel
Chimeric antigen receptor-modified T cells strike back.
@en
Chimeric antigen receptor-modified T cells strike back.
@nl
P2860
P356
P1476
Chimeric antigen receptor-modified T cells strike back.
@en
P2093
Marcela V Maus
Matthew J Frigault
P2860
P304
P356
10.1093/INTIMM/DXW018
P577
2016-03-28T00:00:00Z